The reported rates range from 1.4% for semaglutide to 16% for exenatide extended-release, depending on the specific formulation and study population
Learn more about GLP-1 in this article
Glow-booster for skin Reduces hyper-pigmentation Promotes cellular repair Flushes out toxins & free radicals Try our most-popular fountain of youth boost for radiant skin
Clinical trials showed joint pain rates similar to placebo, indicating no established direct causal relationship
We find that a licensed GLP-1 receptor agonist modulates epigenetic biomarkers of aging, positioning semaglutide as a candidate gerotherapeutic and laying the groundwork for prospectively powered, mechanism-focused trials aimed at extending healthspan in populations vulnerable to accelerated aging
By improving mitochondrial efficiency, it supports energy levels, metabolic balance and overall cellular performance, particularly as the body ages or experiences metabolic stress